In colorectal cancer, CD3, CD4, CD8, CD20, Granzyme B, and FoxP3+ tumor infiltrating lymphocytes (TILs) have been identified as potential indicators of outcome, while the identification of cytotoxic T-lymphocytes, mast cells and dendritic cells as elicitors of anti-tumor responses has underlined new avenues for potential immunotherapies [3], [4], [5]. Here, CD8A is linked to colorectal cancer.